J&J's apalutamide gets Priority Review for CRPC

The Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) said Thursday FDA accepted and granted Priority Review to an NDA for apalutamide (JNJ56021927) to treat non-metastatic castration-resistant prostate cancer. Its PDUFA date is in April 2018...